You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP32)1 Sep 2021MP32-09 MODEST INCREASE IN SURVIVAL AMONG PATIENTS WITH METASTATIC PROSTATE CANCER IN THE SECOND-LINE ANTIANDROGEN THERAPY ERA Isaac Kim, Thomas Jang, Sinae Kim, David Lee, Daniel Kim, Eric Singer, Saum Ghodoussipour, Monish Aron, Marc Dall’Era, and Isaac Kim Isaac KimIsaac Kim More articles by this author , Thomas JangThomas Jang More articles by this author , Sinae KimSinae Kim More articles by this author , David LeeDavid Lee More articles by this author , Daniel KimDaniel Kim More articles by this author , Eric SingerEric Singer More articles by this author , Saum GhodoussipourSaum Ghodoussipour More articles by this author , Monish AronMonish Aron More articles by this author , Marc Dall’EraMarc Dall’Era More articles by this author , and Isaac KimIsaac Kim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002036.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Since 2004, multiple drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Given the recent advent of several blockbuster drugs in the second-line antiandrogen therapies (SAT) class for metastatic prostate cancer since 2010, however, we hypothesized that there would be significant improvements in survival among patients with metastatic prostate cancer from the pre-docetaxel to SAT era (years 2000 to 2016). METHODS: We analyzed the SEER database to assess the survival outcome of metastatic prostate cancer patients since 2000. Overall (OS) and prostate cancer-specific survival (PCSS) were estimated using the Kaplan-Meier product limit method stratified by three time periods, and their differences were analyzed using the log rank test. RESULTS: The study sample consisted of 41,149 patients at least 18-years-old diagnosed with distant prostate cancer between 2000 and 2016. The results demonstrated that there was a statistically significant improvement in overall and prostate cancer-specific survival of 4 and 3 months, respectively, among men diagnosed with metastatic prostate cancer from 2010 to 2016 when compared to those in the pre-2010 period. Interestingly, this survival benefit was limited to patients with bone and visceral metastases (M1b and M1c stage). CONCLUSIONS: Collectively, our observation suggests that new treatment agents such as second-line antiandrogens introduced since 2010 may have contributed to the improvement in survival of metastatic prostate cancer patients. Despite these advances, however, it is important to note that median OS improved by only 4 months. Source of Funding: This work was supported by the cancer center grant from the National Cancer Institute (Grant P30CA072720) and generous support from the Marion and Norman Tanzman Charitable Foundation and Mr. Malcolm Wernik © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e568-e568 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Isaac Kim More articles by this author Thomas Jang More articles by this author Sinae Kim More articles by this author David Lee More articles by this author Daniel Kim More articles by this author Eric Singer More articles by this author Saum Ghodoussipour More articles by this author Monish Aron More articles by this author Marc Dall’Era More articles by this author Isaac Kim More articles by this author Expand All Advertisement Loading ...